BEZ235: When Promising Science Meets Clinical Reality
Open accessAbstract
An article in a recent issue of The Oncologist reports the results of a phase I clinical trial of BEZ235 in patients with advanced renal cell carcinoma. The study was terminated early due to toxicity and a lack of clinical efficacy. The rapid and concise publication of this type of clinical result is necessary for effective collaboration and, ultimately, better outcomes for cancer patients.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Severe toxicity occurred when MEK and PI3K inhibitors were used for treatment in patients with RAS and PIK3CA-mutated CRC.
“However, a previous report uncovered severe toxicity when MEK and PI3K inhibitors were used for treatment in patients with RAS and PIK3CA-mutated CRC37.”
From Mechanisms of KRAS inhibitor resistance in KRAS-mutant colorectal cancer harboring Her2 amplification and aberrant KRAS localization (2025) · cites this paper as [37]
The paper’s Abstract reports grade 3–4 adverse effects with the dual PI3K/mTOR inhibitor BEZ235 in patients with renal cell carcinoma, and poor tolerability in pancreatic neuroendocrine tumors. It does not report toxicity from combined MEK and PI3K inhibitors in patients with RAS- and PIK3CA-mutated colorectal cancer. (LLM, conf=0.86)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590 · see citing works
Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma
Hudes, G. R., Carducci, M. A., Tomczak, P., Dutcher, J. P., Figlin, R. A., Kapoor, A., Starosławska, E., Sosman, J. A., McDermott, D. F., Bodrogi, I., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066838 · Cited by 3,645 · see citing works
Comprehensive molecular characterization of clear cell renal cell carcinoma
The Cancer Genome Atlas Research Network (2013) · Nature · doi:10.1038/nature12222 · Cited by 3,485 · see citing works
Motzer, R. J., Escudier, B., Oudard, S., Hutson, T. E., Porta, C., Bracarda, S., Grünwald, V., Thompson, J. A., Figlin, R. A., Hollaender, N., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61039-9 · Cited by 3,019 · see citing works
Everolimus for Advanced Pancreatic Neuroendocrine Tumors
Yao, J. C., Shah, M. H., Ito, T., Lombard‐Bohas, C., Wolin, E. M., Cutsem, E. V., Hobday, T. J., Okusaka, T., Capdevila, J., de Vries, E. G. E., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009290 · Cited by 2,879 · see citing works
Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
Baselga, J., Campone, M., Piccart, M., Burris, H. A., Rugo, H. S., Sahmoud, T., Noguchi, S., Gnant, M., Pritchard, K. I., Lebrun, F., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1109653 · Cited by 2,863 · see citing works
mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt
O'Reilly, K. E., Rojo, F., She, Q.-B., Solit, D., Mills, G. B., Smith, D., Lane, H., Hofmann, F., Hicklin, D. J., Ludwig, D. L., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2925 · Cited by 2,561 · see citing works
Yao, J. C., Fazio, N., Singh, S., Buzzoni, R., Carnaghi, C., Wolin, E. M., Tomášek, J., Raderer, M., Lahner, H., Voi, M., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)00817-x · Cited by 1,290 · see citing works
Phase 3 trial of everolimus for metastatic renal cell carcinoma
Motzer, R. J., Escudier, B. J., Oudard, S. M., Hutson, T. E., Porta, C., Sergio Bracarda, A., Grünwald, V., Thompson, J. A., Figlin, R. A., Hollaender, N., et al. (2010) · Cancer · doi:10.1002/cncr.25219 · Cited by 1,140 · see citing works
Targeting the translation machinery in cancer
Bhat, M., Robichaud, N., Hulea, L., Sonenberg, N., Pelletier, J., & Topisirovic, I. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4505 · Cited by 799 · see citing works
Regulation of mTORC1 by PI3K Signaling
Dibble, C. C., & Cantley, L. (2015) · Trends in Cell Biology · doi:10.1016/j.tcb.2015.06.002 · Cited by 770 · see citing works
Heß, G., Herbrecht, R., Romaguera, J. E., Verhoef, G. E. G., Crump, M., Gisselbrecht, C., Laurell, A., Offner, F. C., Strahs, A. L., Berkenblit, A., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.7977 · Cited by 641 · see citing works
Dreyling, M. H., Jurczak, W. J., Jerkeman, M., Silva, R. S., Rusconi, C., Trněný, M., Offner, F. C., Caballero, D. M., Joao, C. M., Witzens‐Harig, M., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)00667-4 · Cited by 464 · see citing works
mTOR Kinase Inhibition Causes Feedback-Dependent Biphasic Regulation of AKT Signaling
Rodrik-Outmezguine, V. S., Chandarlapaty, S., Pagano, N. C., Poulikakos, P. I., Scaltriti, M., Moskatel, E., Baselga, J., Guichard, S., & Rosen, N. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0085 · Cited by 442 · see citing works
Ellis, L. M., Bernstein, D. S., Voest, E. E., Berlin, J. D., Sargent, D. J., Cortazar, P., Garrett-Mayer, E. S., Herbst, R. S., Lilenbaum, R., Sima, C. S., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.8009 · Cited by 440 · see citing works
mTOR signaling and drug development in cancer
Dancey, J. E. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.21 · Cited by 418 · see citing works
Hutson, T. E., Escudier, B. J., Esteban, E., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.50.3961 · Cited by 404 · see citing works
A Central Role for mTOR in Lipid Homeostasis
Lamming, D. W., & Sabatini, D. M. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.08.002 · Cited by 361 · see citing works
Multilevel Genomics-Based Taxonomy of Renal Cell Carcinoma
Chen, F., Zhang, Y., Şenbabaoğlu, Y., Ciriello, G., Yang, L., Reznik, E., Shuch, B., Micevic, G., de Velasco, G., Shinbrot, E., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.02.024 · Cited by 360 · see citing works
Coordinated regulation of protein synthesis and degradation by mTORC1
Zhang, Y., Nicholatos, J. W., Dreier, J. R., Ricoult, S. J. H., Widenmaier, S. B., Hotamışlıgil, G. S., Kwiatkowski, D. J., & Manning, B. D. (2014) · Nature · doi:10.1038/nature13492 · Cited by 349 · see citing works
Wolff, A. C., Lazar, A. A., Bondarenko, I., Garin, A. M., Brincat, S., Chow, L. W. C., Sun, Y. P., Nešković‐Konstantinović, Z., Guimarães, R. C., Fumoleau, P., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.3331 · Cited by 272 · see citing works
Rini, B. I., Bellmunt, J., Clancy, J. S., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.50.5305 · Cited by 213 · see citing works
Powles, T. B., Lackner, M. R., Oudard, S. M., Escudier, B. J., Ralph, C., Brown, J. E., Hawkins, R. E., Castellano, D., Rini, B. I., Staehler, M. D., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.8808 · Cited by 135 · see citing works
Carlo, M. I., Molina, A. M., Lakhman, Y., et al. (2016) · The Oncologist · doi:10.1634/theoncologist.2016-0145 · Cited by 101 · see citing works
Fazio, N., Buzzoni, R., Baudin, É., Antonuzzo, L., Hubner, R. A., Lahner, H., de Herder, W. W., Raderer, M., Teulé, À., Capdevila, J., et al. (2016) · PubMed · Cited by 85 · see citing works
Gonzalez-Angulo, A. M., Juric, D., Argilés, G., Schellens, J. H. M., Burris, H. A., Berlin, J. D., Middleton, M. R., Schüler, M., van Geel, R. M. J. M., Helgason, T., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.2531 · Cited by 52 · see citing works
Arkenau, H., Mateo, J., Lemech, C., Infante, J. R., Burris, H. A., Bang, Y., Eder, J. P., Herbst, R. S., Sharma, S., Chung, H. C., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.2514 · Cited by 28 · see citing works
Phase II studies of BEZ235 in patients with advanced pancreatic neuroendocrine tumors (pNET).
Salazar, R., Verslype, C., Baudin, É., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.4102 · Cited by 13 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Wang, B., Zhang, W., Zhang, G., Kwong, L., Lu, H., Tan, J., Sadek, N., Xiao, M., Zhang, J., Labrie, M., et al. (2021) · Oncogene · doi:10.1038/s41388-021-01911-5 · Cited by 66 · see citing works
Jain, A. B., & Lai, V. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01628-0 · Cited by 32 · see citing works
Maruyama, K., Shimizu, Y., Nomura, Y., Oh-hara, T., Takahashi, Y., Nagayama, S., Fujita, N., & Katayama, R. (2025) · npj Precision Oncology · doi:10.1038/s41698-024-00793-6 · Cited by 16 · see citing works
- Authors
- Pongas, G., & Fojo, T.
- Affiliations
- Columbia University Irving Medical Center (US)
- Corresponding author
- Fojo, Tito
- Venue
- The Oncologist
- Publisher
- Oxford University Press (OUP)
- Published
- 2016-08-26
- Volume
- 21
- Issue
- 9
- Pages
- 1033-1034
- ISSN
- 1083-7159 (ISSN-L)
- 1549-490X
- PMC
- PMC5016067
- OpenAlex
- W2514843686
- Semantic Scholar
- c8ff6b82d70ecf0b14db34d4724885b9eef9a3bd
- Cited by
- 43
- References
- 28
- Citations by year
- 2025: 3 · 2024: 4 · 2023: 2 · 2022: 5 · 2021: 8 · 2020: 5 · 2019: 6 · 2018: 6 · 2017: 4
- FWCI
- 4.77
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Locations
- The Oncologist (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Renal cell carcinoma treatment
- Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Keywords
- BEZ235, renal cell carcinoma, early trial termination, drug toxicity, clinical efficacy, translational research, anticancer drug development
- MeSH terms
- Humans, Imidazoles, Quinolines, Phosphatidylinositol 3-Kinases, Cell Line, Tumor, Cell Proliferation, TOR Serine-Threonine Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
